unknown primary neoplasms

Summary

Summary: Metastases in which the tissue of origin is unknown.

Top Publications

  1. ncbi Epidemiology of unknown primary tumours
    F Levi
    Eur J Cancer 38:1810-2. 2002
  2. ncbi Diagnostic and therapeutic management of cancer of an unknown primary
    N Pavlidis
    University of Ioannina Hospital, Department of Medical Oncology, 451 10, Ioannina, Greece
    Eur J Cancer 39:1990-2005. 2003
  3. ncbi Cancer of unknown primary site: missing primary or missing biology?
    George Pentheroudakis
    Department of Medical Oncology, Ioannina University Hospital, Ioannina, Greece
    Oncologist 12:418-25. 2007
  4. ncbi Pathologic evaluation of unknown primary cancer
    Karin A Oien
    Division of Cancer Sciences and Molecular Pathology, Faculty of Medicine, University of Glasgow, United Kingdom
    Semin Oncol 36:8-37. 2009
  5. ncbi Switching benchmarks in cancer of unknown primary: from autopsy to microarray
    George Pentheroudakis
    Department of Medical Oncology, Ioannina University Hospital, Niarxou Avenue, 45500 Ioannina, Greece
    Eur J Cancer 43:2026-36. 2007
  6. ncbi The role of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site
    Pascal Seve
    Department of Internal Medicine, Hotel Dieu, Hospices Civils de Lyon, Lyon, France
    Cancer 109:292-9. 2007
  7. ncbi Clinical and immunohistochemical analysis of patients with unknown primary tumour. A search for prognostic factors in UPT
    Agnes J van de Wouw
    Department of Internal Medicine, University Hospital, Maastricht, The Netherlands
    Anticancer Res 24:297-301. 2004
  8. ncbi The unknown biology of the unknown primary tumour: a literature review
    A J van de Wouw
    Department of Internal Medicine, Slingeland Hospital Doetinchem, Doetinchem, The Netherlands
    Ann Oncol 14:191-6. 2003
  9. ncbi Taxane-based chemotherapy for patients with carcinoma of unknown primary site
    F A Greco
    Sarah Cannon Cancer Center, 250 25th Avenue, North, Suite 412, Nashville, Tennessee 37203-1632, USA
    Cancer J 7:203-12. 2001
  10. ncbi Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm
    Jayne L Dennis
    Cancer Research UK Centre for Oncology and Applied Pharmacology, Beatson Laboratories, University of Glasgow, Garscube Estate, Switchback Road, Glasgow G61 1BD, United Kingdom
    Clin Cancer Res 11:3766-72. 2005

Research Grants

Detail Information

Publications198 found, 100 shown here

  1. ncbi Epidemiology of unknown primary tumours
    F Levi
    Eur J Cancer 38:1810-2. 2002
  2. ncbi Diagnostic and therapeutic management of cancer of an unknown primary
    N Pavlidis
    University of Ioannina Hospital, Department of Medical Oncology, 451 10, Ioannina, Greece
    Eur J Cancer 39:1990-2005. 2003
    ..Empirical chemotherapy benefits some of the patients who do not fit into any favourable sub-set, and should be considered in patients with a good performance status...
  3. ncbi Cancer of unknown primary site: missing primary or missing biology?
    George Pentheroudakis
    Department of Medical Oncology, Ioannina University Hospital, Ioannina, Greece
    Oncologist 12:418-25. 2007
    ..Confirmation of one of the two hypotheses would either improve primary disease-oriented therapy or develop CUP-oriented treatments targeting molecular aberrations that drive neoplastic growth/dissemination...
  4. ncbi Pathologic evaluation of unknown primary cancer
    Karin A Oien
    Division of Cancer Sciences and Molecular Pathology, Faculty of Medicine, University of Glasgow, United Kingdom
    Semin Oncol 36:8-37. 2009
    ..Optimal tissue handling and IHC interpretation, quality assurance, and limitations also are discussed. The target readership is oncologists, but other clinicians and trainee pathologists also may find the content of use...
  5. ncbi Switching benchmarks in cancer of unknown primary: from autopsy to microarray
    George Pentheroudakis
    Department of Medical Oncology, Ioannina University Hospital, Niarxou Avenue, 45500 Ioannina, Greece
    Eur J Cancer 43:2026-36. 2007
    ..We systematically reviewed all published evidence on the CUP primary site identified by two different approaches, either autopsy or microarray gene expression profiling...
  6. ncbi The role of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site
    Pascal Seve
    Department of Internal Medicine, Hotel Dieu, Hospices Civils de Lyon, Lyon, France
    Cancer 109:292-9. 2007
    ..The authors conducted a comprehensive review of the efficacy of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography (FDG-PET) in the detection of primary tumors in patients with disseminated carcinoma of unknown primary site...
  7. ncbi Clinical and immunohistochemical analysis of patients with unknown primary tumour. A search for prognostic factors in UPT
    Agnes J van de Wouw
    Department of Internal Medicine, University Hospital, Maastricht, The Netherlands
    Anticancer Res 24:297-301. 2004
    ....
  8. ncbi The unknown biology of the unknown primary tumour: a literature review
    A J van de Wouw
    Department of Internal Medicine, Slingeland Hospital Doetinchem, Doetinchem, The Netherlands
    Ann Oncol 14:191-6. 2003
    ..g. by applying newly available DNA and gene profiling microarray techniques, will be necessary to understand its specific biology and to develop more effective treatments...
  9. ncbi Taxane-based chemotherapy for patients with carcinoma of unknown primary site
    F A Greco
    Sarah Cannon Cancer Center, 250 25th Avenue, North, Suite 412, Nashville, Tennessee 37203-1632, USA
    Cancer J 7:203-12. 2001
    ..CONCLUSION: Taxane-based chemotherapy for patients with carcinoma of unknown primary site appears to be clinically beneficial and is associated with long-term survival for a minority of patients at 2-, 3-, and 4-year follow-up...
  10. ncbi Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm
    Jayne L Dennis
    Cancer Research UK Centre for Oncology and Applied Pharmacology, Beatson Laboratories, University of Glasgow, Garscube Estate, Switchback Road, Glasgow G61 1BD, United Kingdom
    Clin Cancer Res 11:3766-72. 2005
    ..Knowledge of the primary site is important for their management, but histologically, such tumors appear similar. Better diagnostic markers are needed to enable the assignment of metastases to likely sites of origin on pathologic samples...
  11. pmc Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis
    Thomas C Kwee
    Department of Radiology, University Medical Center Utrecht, Utrecht, The Netherlands
    Eur Radiol 19:731-44. 2009
    ..In conclusion, FDG-PET/CT can be a useful method for unknown primary tumor detection. Future studies are required to prove the assumed advantage of FDG-PET/CT over FDG-PET alone and to further explore causes of heterogeneity...
  12. ncbi Forty years experience of treating cancer of unknown primary
    Nicholas Pavlidis
    Department of Medical Oncology, School of Medicine, University of Ioannina, Ioannina, Greece
    Acta Oncol 46:592-601. 2007
    ..This review article provides both a historical outline of CUP treatment as well as a helpful therapeutic guide to every oncologist who treats CUP patients...
  13. ncbi Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary
    Hugo M Horlings
    Division of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    J Clin Oncol 26:4435-41. 2008
    ..Currently, the success rate of the diagnostic work-up is only 20% to 30%. Our goal was to evaluate the contribution of gene expression profiling for routine clinical practice in patients with ACUP...
  14. ncbi Phase II trial of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site
    Bryan J Schneider
    Division of Hematology Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109 0848, USA
    Cancer 110:770-5. 2007
    ..The purposes of this study were to evaluate efficacy and toxicity of the combination of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site (CUP)...
  15. ncbi Carcinoma of unknown primary site
    F A Greco
    Sarah Cannon Minnie Pearl Cancer Center, Centennial Medical Center, Nashville, TN 36203, USA
    Cancer 89:2655-60. 2000
    ....
  16. ncbi FDG PET and PET/CT for the detection of the primary tumour in patients with cervical non-squamous cell carcinoma metastasis of an unknown primary
    Stefan A M Paul
    Interne Klinik Dr Argirov, Kempfenhausen am Starnberger See, Muenchner Strasse 23 29, 82335, Berg, Germany
    Eur Arch Otorhinolaryngol 264:189-95. 2007
    ....
  17. ncbi Whole body 18F-FDG PET/CT imaging in the detection of primary tumours in patients with a metastatic carcinoma of unknown origin
    Ali Osman Kaya
    Gazi University, School of Medicine, Department of Medical Oncology, Turkey
    Asian Pac J Cancer Prev 9:683-6. 2008
    ..The aim of this study was to evaluate the role of whole body 18F-FDG PET/CT imaging in the detection of primary tumors in patients with a metastatic cancer from an unknown primary site...
  18. ncbi An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin
    Richard W Tothill
    Ian Potter Centre for Cancer Genomics and Predictive Medicine, Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, St Andrew s Place, East Melbourne, Victoria, Australia
    Cancer Res 65:4031-40. 2005
    ..We show that the microarray SVM classifier was capable of making high confidence predictions in 11 of 13 cases. These predictions were supported by comprehensive review of the patients' clinical histories...
  19. pmc A quantitative reverse transcriptase-polymerase chain reaction assay to identify metastatic carcinoma tissue of origin
    Dimitri Talantov
    Veridex LLC, 33 Technology Dr, Warren, NJ 07059, USA
    J Mol Diagn 8:320-9. 2006
    ..Lastly, our assay demonstrated an accuracy of 76% when tested on an independent set of 48 metastatic samples, 37 of which were either a known primary or initially presented as carcinoma of unknown primary but were subsequently resolved...
  20. pmc Carboplatin, doxorubicin and etoposide in the treatment of tumours of unknown primary site
    A Piga
    Department of Medical Oncology, University of Ancona, Italy
    Br J Cancer 90:1898-904. 2004
    ..Efforts should therefore be addressed to identify predictors of response to chemotherapy, thus limiting aggressive treatment to those patients who could benefit from it...
  21. ncbi Combination chemotherapy with gemcitabine and irinotecan in patients with previously treated carcinoma of an unknown primary site: a Minnie Pearl Cancer Research Network Phase II trial
    John D Hainsworth
    Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, Tennessee 37203, USA
    Cancer 104:1992-7. 2005
    ..The current study was performed to evaluate the activity of combination chemotherapy with gemcitabine and irinotecan in patients with previously treated carcinoma of an unknown primary site...
  22. ncbi Unknown primary tumors: detection with dual-modality PET/CT--initial experience
    Andreas Gutzeit
    Department of Diagnostic and Interventional Radiology, University Hospital of Essen, Hufelandstrasse 55, 45122 Essen, Germany
    Radiology 234:227-34. 2005
    ..To retrospectively evaluate fused positron emission tomography (PET)/computed tomography (CT) in depicting the primary lesion in cancer of an unknown primary tumor, compared with PET, CT, and PET and CT side-by-side evaluation...
  23. ncbi Alternative bimonthly cycles of doxorubicin, cyclophosphamide, and etoposide, cisplatin with hematopoietic growth factor support in patients with carcinoma of unknown primary site
    Stephane Culine
    Centre Regional de Lutte contre le Cancer Val d Aurelle, Montpellier, France
    Cancer 94:840-6. 2002
    ....
  24. ncbi Molecular profiling of a tumor of unknown origin
    Gustavo Ismael
    N Engl J Med 355:1071-2. 2006
  25. pmc Gemcitabine and carboplatin in carcinoma of unknown primary site: a phase 2 Adelaide Cancer Trials and Education Collaborative study
    K B Pittman
    Department of Oncology, The Queen Elizabeth Hospital, Woodville Road, Woodville, South Australia, Australia
    Br J Cancer 95:1309-13. 2006
    ..The regimen was very well tolerated, particularly in the elderly. The GC regimen is an active regimen in CUP with excellent tolerability and should be considered particularly for elderly patients with CUP...
  26. ncbi Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site
    Damien Pouessel
    Department of Medical Oncology, Centre Regional de Lutte contre le Cancer Val d Aurelle, Montpellier, France
    Cancer 100:1257-61. 2004
    ..The current study was performed to evaluate the efficacy and toxicity of a noncisplatin-based chemotherapy regimen combining gemcitabine and docetaxel as front-line chemotherapy for patients with carcinoma of an unknown primary site...
  27. ncbi A phase II study of carboplatin and paclitaxel in adenocarcinoma of unknown primary
    Basil F El-Rayes
    Karmanos Cancer Institute, Wayne State University, Detroit, Michigan 48201, USA
    Am J Clin Oncol 28:152-6. 2005
    ..This study was conducted to evaluate the efficacy and toxicity of combination carboplatin and paclitaxel in patients with adenocarcinoma of unknown primary site (ACUP)...
  28. ncbi Cancer of unknown primary site: review of consecutive cases at the National Cancer Center Hospital of Japan
    Satomi Yakushiji
    Breast and Medical Oncology Division, Department of Medical Oncology, National Cancer Center Hospital, 1 1 Tsukiji 5 chome, Chuo Ku, Tokyo 104 0045, Japan
    Int J Clin Oncol 11:421-5. 2006
    ..Cancer of unknown primary (CUP) is not a rare clinical entity, accounting for 3%-5% of all solid malignancies...
  29. ncbi Identification from public data of molecular markers of adenocarcinoma characteristic of the site of origin
    Jayne L Dennis
    Cancer Research UK Department of Medical Oncology, University of Glasgow, Cancer Research UK Beatson Laboratories, Scotland, United Kingdom
    Cancer Res 62:5999-6005. 2002
    ..Analysis of public gene expression data sets is a powerful method for the identification of clinically relevant tumor markers...
  30. ncbi Localised disease in cancer of unknown primary (CUP): the value of positron emission tomography (PET) for individual therapeutic management
    D Rades
    Department of Radiation Oncology, Hannover Medical College, Germany
    Ann Oncol 12:1605-9. 2001
    ..After conservative diagnostic procedures including MRI, the primary is detected in less than 25%. The diagnostic value of PET and its influence on therapeutic strategies was evaluated...
  31. ncbi Unknown primary carcinoma: a feasibility assessment of combination chemotherapy with cisplatin and docetaxel
    Hirofumi Mukai
    Department of Medical Oncology, National Cancer Center Hospital, 5 5 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Int J Clin Oncol 8:23-5. 2003
    ..We examined the feasibility of using a combination of docetaxel and cisplatin for the treatment of unknown primary carcinoma in order to prepare a larger scale prospective study...
  32. ncbi CUP (carcinoma of unknown primary) syndrome in head and neck: clinic, diagnostic, and therapy
    A Weber
    Klinik für Hals Nasen Ohren Heilkunde Plastische Operationen, Universitat Leipzig
    Onkologie 24:38-43. 2001
    ..Between 70 and 80% of the found primary tumors are located in the head and neck region, because cervical lymph nodes represent the lymph drainage of the head and neck...
  33. ncbi Diagnostic strategies for unknown primary cancer
    Gauri R Varadhachary
    Department of Gastrointestinal Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer 100:1776-85. 2004
    ..The authors discuss the role of histochemical markers in the diagnosis of UPC and the most recent data regarding the use of imaging and invasive diagnostic modalities and gene expression profiles...
  34. ncbi Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01)
    Stephane Culine
    Department of Medical Oncology, Centre Regional de Lutte Contre le Cancer, Val d Aurelle, Parc Euromedecine, 34298 Montpellier Cedex 5, France
    J Clin Oncol 21:3479-82. 2003
    ..To evaluate the efficacy and toxicity of novel chemotherapy combinations including cisplatin with gemcitabine (GC) or irinotecan (IC) for patients with carcinomas of an unknown primary site...
  35. ncbi Carcinoma of unknown primary site: sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan: a Minnie Pearl Cancer Research Network phase II trial
    F Anthony Greco
    Sarah Cannon Cancer Center, 250 25th Avenue North, Suite 110, Nashville, Tennessee 37203, USA
    Oncologist 9:644-52. 2004
    ....
  36. pmc Gene expression profiling may improve diagnosis in patients with carcinoma of unknown primary
    J Bridgewater
    University College London Cancer Institute, London WC1E 6DD, UK
    Br J Cancer 98:1425-30. 2008
    ..We propose that GEM diagnosis be considered when the primary clinical algorithm has failed to provide a diagnosis...
  37. ncbi A phase II study of paclitaxel plus cisplatin chemotherapy in an unfavourable group of patients with cancer of unknown primary site
    Yeon Hee Park
    Department of Internal Medicine, Korea Institute of Radiological and Medical Sciences, Seoul, Korea
    Jpn J Clin Oncol 34:681-5. 2004
    ..Efficacy was evaluated in terms of response rate, progression-free survival and overall survival...
  38. ncbi Gemcitabine in the second-line therapy of patients with carcinoma of unknown primary site: a phase II trial of the Minnie Pearl Cancer Research Network
    J D Hainsworth
    Sarah Cannon Minnie Pearl Cancer Center, Centennial Medical Center, Nashville, Tennessee, USA
    Cancer Invest 19:335-9. 2001
    ..Because gemcitabine has activity against a variety of adenocarcinomas, further evaluation of this agent as part of first-line therapy for patients with carcinoma of unknown primary site is appropriate...
  39. ncbi Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network
    John D Hainsworth
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    J Clin Oncol 25:1747-52. 2007
    ..We therefore have evaluated the efficacy and toxicity of this combination in patients with CUP...
  40. doi Cancers of unknown primary site: ESMO clinical recommendation for diagnosis, treatment and follow-up
    E Briasoulis
    Department of Medical Oncology, University of Ioannina, Ioannina Ipiros, Greece
    Ann Oncol 19:ii106-7. 2008
  41. ncbi Multicenter phase-II trial of irinotecan plus oxaliplatin [IROX regimen] in patients with poor-prognosis cancer of unknown primary: a hellenic cooperative oncology group study
    E Briasoulis
    Ioannina University Hospital, Ioannina, Greece
    Cancer Chemother Pharmacol 62:277-84. 2008
    ..We evaluated the irinotecan-oxaliplatin combination (IROX regimen) in previously untreated patients with non-favorable subsets of unknown primary carcinomas...
  42. ncbi In search of an unknown primary tumour presenting with cervical metastases: performance of hybrid FDG-PET-CT
    Myriam Wartski
    Nuclear Medicine Department of Cancer Research Center Rene Huguenin, Saint Cloud, France
    Nucl Med Commun 28:365-71. 2007
    ....
  43. ncbi Carcinoma of unknown primary (CUP)
    Nicholas Pavlidis
    School of Medicine, Department of Medical Oncology, University of Ioannina, P O Box 1186, 451 10 Ioannina, Greece
    Crit Rev Oncol Hematol 69:271-8. 2009
    ..Patients who belong to the non-favourable sub-sets have a worse prognosis...
  44. ncbi Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation
    Gauri R Varadhachary
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 26:4442-8. 2008
    ..To evaluate the feasibility of a 10-gene reverse transcriptase polymerase chain reaction assay to identify the tissue of origin in patients with carcinoma of unknown primary (CUP) site...
  45. ncbi 18F-FDG PET/CT in the assessment of carcinoma of unknown primary origin
    V Ambrosini
    Unità Operativa di Medicina Nucleare, Padiglione 30, Policlinico S Orsola Malpighi, Via Massarenti 9, I 40138, Bologna, Italy
    Radiol Med 111:1146-55. 2006
    ..The aim of this study was to assess the role of 18F-fluorodeoxyglucose (FDG) PET/computed tomography (CT) in the identification of occult primary cancers...
  46. ncbi Utility of combined (18)F-fluorodeoxyglucose-positron emission tomography and computed tomography in patients with cervical metastases from unknown primary tumors
    Jong Lyel Roh
    Department of Otolaryngology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
    Oral Oncol 45:218-24. 2009
    ..8% vs. 96.5%). FDG-PET/CT correctly detected distant metastases in 6 of 6 patients. Combined FDG-PET/CT is a useful screening method for primary tumor detection, accurate nodal staging, and distant metastases in patients with CUPs...
  47. ncbi Dual modality of 18F-fluorodeoxyglucose-positron emission tomography/computed tomography in patients with cervical carcinoma of unknown primary
    Lutz S Freudenberg
    Clinic of Nuclear Medicine, University Hospital Essen, Essen, Germany
    Med Princ Pract 14:155-60. 2005
    ....
  48. ncbi The value of postmortem examination in cases of metastasis of unknown origin-20-year retrospective data from a tertiary care center
    Nabeel Al-Brahim
    Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada
    Ann Diagn Pathol 9:77-80. 2005
    ..To evaluate the value of autopsy in determining the primary site of MUO, this study reviewed the Hamilton experience-over the last 20 years-with patients autopsied with clinical diagnosis of MUO...
  49. ncbi FDG-PET in the clinical management of carcinoma of unknown primary with metastatic cervical lymphadenopathy: shifting gears from detecting the primary to planning therapeutic strategies
    Sandip Basu
    Eur J Nucl Med Mol Imaging 34:427-8. 2007
  50. ncbi Cancer of unknown primary origin: a decade of experience in a community-based hospital
    Jose M Pimiento
    Department of Surgery, Saint Mary s Health System, 56 Franklin St, Waterbury, CT 06702, USA
    Am J Surg 194:833-7; discussion 837-8. 2007
    ..Cancer of unknown primary (CUP) origin is a very aggressive disease with a poor prognosis. Most of the literature reports of CUP are generated from tertiary cancer centers...
  51. ncbi Role of 18F-FDG PET-CT imaging for the detection of an unknown primary tumour: preliminary results in 21 patients
    C Nanni
    Nuclear Medicine Service PET Unit, S Orsola Malpighi Bologna Hospital, Bologna, Italy
    Eur J Nucl Med Mol Imaging 32:589-92. 2005
    ..The aim of this study was to evaluate the potential additional diagnostic role of fused 18F-FDG PET-CT imaging for the detection of metastatic occult primary tumours...
  52. ncbi Carcinoma of unknown primary with a colon-cancer profile-changing paradigm and emerging definitions
    Gauri R Varadhachary
    Department of Gastrointestinal Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Lancet Oncol 9:596-9. 2008
    ..In the era of molecular profiling, we expect that additional work with CCP-CUP and other CUP subsets will provide attractive tailored treatment alternatives, with efficacies that exceed the current one-treatment-fits-all approach...
  53. ncbi Prognostic and diagnostic accuracy of [18F]FDG-PET/CT in 190 patients with carcinoma of unknown primary
    Pavel Fencl
    PET Center, Na Homolce Hospital, Roentgenova 2, 150 30 Prague 5, Czech Republic
    Eur J Nucl Med Mol Imaging 34:1783-92. 2007
    ..The aim of the study was to determine the accuracy of [(18)F]fluorodeoxyglucose (FDG) PET/CT in the search for the primary and the presence of a malignancy. The prognostic value of FDG-PET/CT information was tested...
  54. ncbi Molecular classification of unknown primary cancer
    Richard A Bender
    Agendia, Inc, Huntington Beach, CA 92647, USA
    Semin Oncol 36:38-43. 2009
    ..The genomic classification is then available to the pathologist and clinician to aid in both the patient's diagnosis and treatment planning. The impact of this new technology on patient outcomes is currently under study...
  55. ncbi Management of the unknown primary carcinoma: long-term follow-up on a negative PET scan and negative panendoscopy
    Frank R Miller
    Department of Otolaryngology HNS, University of Texas Health Science Center San Antonio, 7703 Floyd Curl Dr, San Antonio, Texas 78229
    Head Neck 30:28-34. 2008
    ..More recently, positron emission tomography (PET) has been advocated as a tool to detect primary tumors...
  56. pmc Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?
    C Massard
    Department of Medicine, Institut Gustave Roussy, 39 rue Camille Desmoulins, Villejuif 94805, France
    Br J Cancer 97:857-61. 2007
    ..This finding may prompt clinical trials investigating EGFR inhibitors in this setting. In contrast, c-Kit expression and Her-2/neu overexpression occur infrequently in CUP. EGFR expression was correlated to tumour chemosensitivity...
  57. ncbi Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site
    Pascal Seve
    Department of Internal Medicine, Hotel Dieu, Hospices Civils de Lyon, Lyon, France
    Cancer 107:2698-705. 2006
    ..The authors investigated how lymphopenia and low serum albumin levels correlate with the prognosis of patients with carcinoma of unknown primary (CUP)...
  58. ncbi [Contribution of 18-F-FDG PET for detection of head and neck carcinomas with an unknown primary tumor]
    N Fakhry
    Service d ORL et de Chirurgie Cervico Faciale du Professeur Zanaret, CHU La Timone, 264, rue Saint Pierre, 13385 Marseille Cedex 05
    Ann Otolaryngol Chir Cervicofac 123:17-25. 2006
    ..To evaluate the usefulness of fusioning positron emission tomography with computed tomography (PET/CT) for the detection of head and neck carcinomas of unknown primary...
  59. ncbi Role of whole body positron emission tomography/computed tomography scan with 18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site
    E Pelosi
    University Nuclear Medicine Service, ASO S Giovanni Battista, Turin, Italy
    Q J Nucl Med Mol Imaging 50:15-22. 2006
    ..The aim of this study was to evaluate the role of whole body PET/CT scan with (18)F-fluorodeoxyglucose (FDG) in the detection of the primary tumor in patients with metastatic cancer from unknown primary origin (CUP syndrome)...
  60. ncbi [The integrated PET/CT: technological advance in diagnostics of head and neck recurrencies and CUP?]
    K Schneider
    Klinik für Hals Nasen Ohren Krankheiten, Plastische Operationen, Klinikum Stuttgart, Katharinenhospital
    Laryngorhinootologie 85:179-83. 2006
    ..The correlation of FDG hypermetabolism and anatomical structures is now provided by a new technology which is integrating PET and CT: Integrated PET/CT represents a new technical development, which combines the advantages of CT and PET...
  61. ncbi [Significance of PET and integrated PET/CT in the diagnostics of occult primary tumors]
    K Schneider
    Klinik für Hals Nasen Ohren Krankheiten, Plastische Operationen, Klinikum Stuttgart, Katharinenhospital
    Laryngorhinootologie 85:819-23. 2006
    ..This retrospective study shows 47 patients with neck metastases where PET or PET/CT helped to detect primary tumor site...
  62. ncbi Breast MR imaging in patients with axillary node metastases and unknown primary malignancy
    S G Orel
    Department of Radiology, University of Pennsylvania Medical Center, Philadelphia 19104, USA
    Radiology 212:543-9. 1999
    ..To assess the usefulness of magnetic resonance (MR) imaging of the breast in patients with malignant axillary adenopathy and unknown primary malignancy...
  63. ncbi Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984-1992
    A J van de Wouw
    Department of Internal Medicine, Slingeland Hospital Doetinchem, The Netherlands
    Eur J Cancer 38:409-13. 2002
    ..In conclusion, we have demonstrated in a population-based study that the prognosis for patients with UPT is more unfavourable than suggested in most clinical studies...
  64. ncbi [PET/CT imaging in head and neck tumors]
    R Rödel
    Klinik und Poliklinik fur Nuklearmedizin, Universitatsklinikum Bonn
    Radiologe 44:1055-9. 2004
    ..To evaluate the usefulness of combined PET/CT examinations for detection of malignant tumors and their metastases in head and neck oncology...
  65. ncbi Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study
    F Anthony Greco
    Sarah Cannon Cancer Center and Tennessee Oncology, Professional Limited Liability Corporation, Centennial Medical Center, Nashville, TN 37203, USA
    J Clin Oncol 20:1651-6. 2002
    ..To evaluate the efficacy and toxicity of the novel chemotherapy combination that includes gemcitabine, carboplatin, and paclitaxel in the treatment of patients with carcinoma of unknown primary site...
  66. ncbi Diagnostic strategies in cervical carcinoma of an unknown primary (CUP)
    Inge Haas
    Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital, Heinrich Heine University, Moorenstrasse 5, 40225 Dusseldorf, Germany
    Eur Arch Otorhinolaryngol 259:325-33. 2002
    ..In patients with cervical CUP, blind but systematic pharyngeal biopsies, including bilateral tonsillectomy, should be performed...
  67. pmc Cytogenetic profile of unknown primary tumors: clues for their pathogenesis and clinical management
    Dimitra Pantou
    Department of Genetics, G Papanikolaou Research Center, Saint Savas Regional Oncological Hospital of Athens, Athens, Greece
    Neoplasia 5:23-31. 2003
    ....
  68. ncbi Meta-analysis of the performance of 18F-FDG PET in primary tumor detection in unknown primary tumors
    Roberto C Delgado-Bolton
    Department of Nuclear Medicine, Hospital Clinico San Carlos, c o Prof Martín Lagos s n, Madrid 18040, Spain
    J Nucl Med 44:1301-14. 2003
    ..The aim of this study was to perform a meta-analysis of the literature to evaluate the accuracy of (18)F-FDG PET in primary tumor detection in patients with UPT...
  69. ncbi Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site
    Stephane Culine
    Centre Regional de Lutte contre le Cancer Val d Aurelle, Montpellier, France
    J Clin Oncol 20:4679-83. 2002
    ..To identify clinical and biologic variables with significant impact on survival in patients with carcinomas of an unknown primary site and to develop a simple prognostic model for the selection of patients in prospective clinical trials...
  70. ncbi Management and outcome of cervical lymph node metastases of unknown primary sites: a retrospective study
    Y Yalin
    Department of Head and Neck Surgery, Cancer Institute, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 1000021, PR China
    Br J Oral Maxillofac Surg 40:484-7. 2002
    ..For metastatic masses in the supraclavicular region, chemotherapy was the preferred treatment. The overall survival for the 107 patients who completed the follow up was 36%...
  71. ncbi Cancer of unknown primary: clinicopathologic correlations
    Hagen Blaszyk
    Mayo Clinic and Foundation, Rochester, MN, USA
    APMIS 111:1089-94. 2003
    ..Our findings show that (1) autopsy studies provide a valuable tool for quality control in the setting of CUP, and (2) treated patients have a small but significant survival benefit...
  72. ncbi Neoplasms of unknown primary site: a clinicopathological study of autopsied patients
    J I Mayordomo
    Department of Medical Oncology, 12 de Octubre University Hospital, Madrid, Spain
    Tumori 79:321-4. 1993
    ..4) Image tests were often misleading as regards the primary site, although they were useful to quantify the dissemination of the tumor...
  73. ncbi Neuroendocrine (Merkel cell) carcinoma in regional lymph nodes without primary site
    Eldad Silberstein
    Center of R and D in Plastic Surgery, Soroka University Medical Center, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel
    Isr Med Assoc J 5:450-1. 2003
  74. ncbi Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study
    E Briasoulis
    Departments of Medical Oncology, Ioannina University Hospital, Greece
    J Clin Oncol 18:3101-7. 2000
    ..To evaluate the efficacy of the carboplatin/paclitaxel combination in patients with carcinoma of unknown primary site (CUP)...
  75. ncbi The role of fluorodeoxyglucose positron emission tomography in cervical lymph node metastases from an unknown primary tumor
    Kyle E Rusthoven
    Department of Radiation Oncology, Emory Clinic Emory University, Atlanta, Georgia, USA
    Cancer 101:2641-9. 2004
    ..The authors performed a comprehensive review of the efficacy of fluorodeoxyglucose positron emission tomography (FDG-PET) in the detection of primary tumors in patients with cervical metastases from unknown primary tumors...
  76. ncbi Combination of cisplatin-doxorubicin-cyclophosphamide in adenocarcinoma of unknown primary site: a phase II trial
    E Guardiola
    Centre Antoine Lacassagne, Nice, France
    Am J Clin Oncol 24:372-5. 2001
    ..However, the emergence of long-term survivors among responder patients highlighted the need to search for an active treatment for patients with ACUP...
  77. ncbi Nodal neuroendocrine (Merkel cell) carcinoma without an identifiable primary tumor
    Hiroko Kuwabara
    Acta Cytol 47:515-7. 2003
  78. ncbi Carcinoma of an unknown primary site: a chemotherapy strategy based on histological differentiation--results of a prospective study
    M Saghatchian
    Institut Gustave Roussy, Villejuif, France
    Ann Oncol 12:535-40. 2001
    ..To evaluate the efficacy and toxicity of a chemotherapy strategy based on histological differentiation, for patients with carcinoma of unknown primary site...
  79. ncbi Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site : results of an Italian multicenter, randomized, phase II study
    Sergio Palmeri
    Department of Oncology, Division of Medical Oncology, University of Palermo, Palermo, Italy
    Cancer 107:2898-905. 2006
    ..To date, the standard treatment for patients who have carcinoma of unknown primary site has not been established...
  80. pmc A phase II study of mitomycin C, cisplatin and continuous infusion 5-fluorouracil (MCF) in the treatment of patients with carcinoma of unknown primary site
    A Graham Macdonald
    ANCHOR Unit, Aberdeen Royal Infirmary, Aberdeen AB25 2ZN, Scotland, UK
    Br J Cancer 86:1238-42. 2002
    ..Survival at 1 year was 28%, and at 2 years, 10%. MCF is a tolerable regimen with comparable toxicity, response rates and survival data to most platinum-based combination chemotherapy regimens in use for this devastating disease...
  81. ncbi Peritoneal carcinomatosis of unknown primary site in women. A distinctive subset of adenocarcinoma
    C M Strnad
    Vanderbilt University Medical Center, Nashville, Tennessee
    Ann Intern Med 111:213-7. 1989
    ..To define the clinical features and results of systemic treatment in women with adenocarcinoma of unknown primary site involving predominantly the peritoneal surfaces...
  82. ncbi Implication of 18F-fluoro-2-deoxy-D-glucose positron emission tomography on management of carcinoma of unknown primary in the head and neck: a Danish cohort study
    Jørgen Johansen
    Department of Oncology, Rigshospitalet, University Hospital of Copenhagen, Denmark
    Laryngoscope 112:2009-14. 2002
    ....
  83. ncbi [Clinical analysis of cervical metastatis from an unknown primary carcinoma]
    Takafumi Takemura
    Department of Otorhinolaryngology Head and Neck Surgery Kumamoto Medical University, Kumamoto
    Nihon Jibiinkoka Gakkai Kaiho 108:996-1003. 2005
    ..Radiotherapy with radical neck dissection was thought more effective than radical neck dissection for local and neck control...
  84. ncbi The usefulness of fluorine 18-labelled deoxyglucose positron emission tomography in the investigation of patients with cervical lymphadenopathy from an unknown primary tumor
    Gerald B Fogarty
    Division of Radiation Oncology, Peter MacCallum Cancer Institute, Locked Bag 1, A Beckett St, Victoria 8006, Australia
    Head Neck 25:138-45. 2003
    ..To assess the role of PET in this scenario in our institution, an audit was performed...
  85. ncbi Lymph node metastasis of squamous cell carcinoma from an unknown primary: impact of positron emission tomography
    Sandro J Stoeckli
    Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Zurich, Zurich, Switzerland
    Eur J Nucl Med Mol Imaging 30:411-6. 2003
    ..Considering its high specificity, PET could be of value as an initial evaluation instrument, reserving the need for extensive work-up to patients with negative scans...
  86. ncbi [Simultaneous manifestation of blue-rubber-bleb-nevus-syndrome and malignant melanoma]
    S Kinner
    Institut fur Diagnostische und Interventionelle Radiologie und Neuroradiologie, Universitatsklinikum Essen
    Vasa 35:239-41. 2006
    ..Little is known about coherence between these nevi and malignant diseases. We report on a young man with progressive BRBN syndrome representing a thitherto unknown malignant melanoma...
  87. pmc PET in face and neck tumours
    Sheila C Rankin
    Guy s and St Thomas Foundation Trust, London, UK
    Cancer Imaging 6:S89-95. 2006
    ..It can be used to stage the primary tumour, to assess response to therapy and most importantly for the detection of recurrent tumour. The advantages and limitations of this technique are discussed in this article...
  88. ncbi [Current trends in diagnosis and treatment head and neck cancer]
    Jean Lacau Lacau St Guily
    Service d ORL et Chirurgie Cervico Faciale, hôpital Tenon and UFR Pierre et Marie Curie, Universite Paris 6, 75970 Paris
    Rev Prat 56:1652-7. 2006
    ..In neck carcinoma with unknown primary, search of primary should address first head and neck area and upper aero-digestive tract. Differential diagnosis are glomic tumour, congenital cyst and other causes of lymph node disease..
  89. ncbi Lymph node metastases in the neck from unknown primary tumour
    J Jakobsen
    Department of Otorhinolaryngology, Odense University Hospital, Denmark
    Acta Oncol 31:653-5. 1992
    ..Patients with small neck node metastases responded well to treatment with neck dissection and radiotherapy, resulting in a 5-year crude survival rate of 53%...
  90. ncbi Metastatic carcinoma to the cervical nodes from an unknown head and neck primary site: Is there a need for neck dissection?
    Maryam Aslani
    Department of Radiation Oncology, McGill University, Montreal, Quebec, Canada
    Head Neck 29:585-90. 2007
    ....
  91. ncbi Multiple hemorrhagic strokes from DIC associated with occult large cell carcinoma
    Matthew A Koenig
    Division of Neurosciences Critical Care, Johns Hopkins Hospital, Baltimore, MD, USA
    Neurocrit Care 5:210-2. 2006
    ..Multiple hemorrhagic strokes are a rare presentation of paraneoplastic disseminated intravascular coagulation (DIC). We present a case of DIC occurring in a patient with occult large cell carcinoma...
  92. ncbi Prospective study of 18FDG-PET in the detection and management of patients with lymph node metastases to the neck from an unknown primary tumor. Results from the DAHANCA-13 study
    Jørgen Johansen
    Department of Oncology, Odense University Hospital, Odense, Denmark
    Head Neck 30:471-8. 2008
    ..The benefit of a complementary fluorodeoxyglucose-positron emission tomography (FDG-PET) scan to standard workup for carcinoma of unknown primary (CUP) and metastatic neck lesions was prospectively studied...
  93. ncbi Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: a multicentre Hellenic Cooperative Oncology Group phase II study
    George Pentheroudakis
    Ioannina University Hospital, Ioannina, Greece
    Acta Oncol 47:1148-55. 2008
    ..Taxane/platinum combinations exhibit synergistic cytotoxicity and activity against a broad range of solid tumours. We sought to optimise the regimen as a suitable outpatient palliative treatment for cancer of unknown primary (CUP)...
  94. ncbi [Positron emission tomography in head and neck oncology: five cases]
    A Courtois
    Service ORL et Chirurgie Cervico-Faciale, HIA Ste Anne, BP 600, 83800 Toulon Naval
    Ann Otolaryngol Chir Cervicofac 118:254-60. 2001
    ..18-FDG-PET is currently under evaluation as a tool for detecting cervical lymph nodes and early assessment of response to chemotherapy...
  95. ncbi [Clinical study of 28 cases of cervical lymph node metastasis from an unknown primary carcinoma]
    Takamasa Tagawa
    Department of Otorhinolaryngology, Keio University School of Medicine
    Nihon Jibiinkoka Gakkai Kaiho 110:506-12. 2007
    ..Overall 5-year survival in this study was 46%. We should pay particular attention to the tonsils for detecting primary tumors in patients with cervical metastasis from an unknown primary carcinoma...
  96. ncbi An unusual mucin-secreting neoplasm presenting as a metastasis in the neck
    M Aron
    Cytopathology 18:203-6. 2007
  97. ncbi Cervical nodal metastases from occult primary: undifferentiated carcinoma versus squamous cell carcinoma
    Chi Chung Tong
    Department of Clinical Oncology, Queen Elizabeth Hospital, 30 Gascoigne Road, Kowloon, Hong Kong
    Head Neck 24:361-9. 2002
    ..Oncologists face a major challenge in adopting an optimal approach. This study attempted to compare the clinical course of two different histologic findings of this disease entity...
  98. ncbi Carcinoma metastatic to cervical lymph nodes from an occult primary tumor: the outcome after combined-modality therapy
    Paolo Boscolo-Rizzo
    ENT Department and Regional Center for Head and Neck Cancer, University of Padua, School of Medicine, Treviso Regional Hospital, Treviso, Italy
    Ann Surg Oncol 14:1575-82. 2007
    ..The aim of this retrospective analysis was to analyze the results of treatment of patients with cervical node metastases from carcinoma of occult primary with a policy including neck dissection and postoperative comprehensive radiotherapy...
  99. ncbi Evaluation of the role of 18FDG-PET/CT in radiotherapy target definition in patients with head and neck cancer
    Katie L Newbold
    The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK
    Acta Oncol 47:1229-36. 2008
    ..This study evaluated the impact of (18)FDG-PET/CT on radiotherapy target volume definition in head and neck cancer (HNC)...
  100. ncbi [Correlation of FDG-PET and MRI/CT with histopathology in primary diagnosis, lymph node staging and diagnosis of recurrency of head and neck cancer]
    G Popperl
    Klinik und Poliklinik für Nuklearmedizin München, Germany
    Rofo 174:714-20. 2002
    ....
  101. ncbi Role of tonsillectomy in the search for a squamous cell carcinoma from an unknown primary in the head and neck
    Prasad Kothari
    Department of Otolaryngology and Head and Neck Surgery, Northwick Park Hospital, London, United Kingdom
    Br J Oral Maxillofac Surg 46:283-7. 2008
    ..We therefore recommend that bilateral tonsillectomy should be standard in the investigation of patients who present with cervical metastases from an unknown primary in the head and neck region...

Research Grants6

  1. BREAST CANCER STAGING WITH MRI PRIOR RE-EXCISION
    Susan Orel; Fiscal Year: 2001
    ..Correlation of MRI, mammographic, clinical, and pathological findings will generate a profile of patients at risk for occult, diffuse or multifocal disease who should undergo MRI prior to treatment recommendation. ..
  2. MELANOMA ANTIGENS INDENTIFIED FROM GMCSF VACCINATION
    FRANK HODI; Fiscal Year: 2002
    ..Further identification of immunogenic antigens in melanoma offers promise for future therapies. ..
  3. RAP1A AND RAP1B IN THE DIAGNOSIS AND TMT - ORAL CANCER
    NISHA D SILVA; Fiscal Year: 2004
    ..The third segment involves the design of a protocol to investigate the use of rap1A in gene therapy to treat residual epithelial dysplasia or squamous cell carcinoma lesions. ..
  4. CTLA-4 Blockade in GM-CSF Vaccinated Patients
    FRANK HODI; Fiscal Year: 2004
    ..abstract_text> ..
  5. Rap 1-Mediated Protein Transport in Oral Cancer
    NISHA D SILVA; Fiscal Year: 2006
    ..The significance of this research is that it explores an important and novel mechanism for nucleocytoplasmic transport of pro-proliferative proteins in oral cancer, thereby identifying novel treatment targets. [unreadable] [unreadable]..
  6. Effective surveillance strategies for melanoma patients
    Janice N Cormier; Fiscal Year: 2010
    ..Collectively, the outcomes from this proposal will provide evidence-based guidelines for surveillance, which in turn will promote the cost-effective use of health care resources. ..